Search

Search Constraints

You searched for: Author/Creator Quinn, Matt

Search Results

2. Umibecestat in the API Generation program: Worsening in RBANS and/or CDR on treatment reverses after wash‐out: Alzheimer's Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up. (7th December 2020)

3. The API Generation program: Biomarker phenotyping of cognitively unimpaired participants screened in Generation study 1 and Generation study 2: Alzheimer's Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up. (7th December 2020)

4. The API Generation program: Umibecestat treatment and discontinuation effects on hippocampal and whole brain volumes in the overall population and amyloid‐negative APOE4 homozygotes: Alzheimer's Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up. (7th December 2020)

5. The Generation program: Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation study 1 and Generation study 2: Alzheimer's Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up. (7th December 2020)

6. The Alzheimer's prevention initiative Generation program: A global perspective on best practices for site support and engagement to accelerate participant recruitment: Clinical trial design and implementation. (7th December 2020)